Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

14 de março de 2019 atualizado por: Astellas Pharma Inc

A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus

The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

43

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aichi, Japão
        • Site JP00006
      • Fukuoka, Japão
        • Site JP00002
      • Gunma, Japão
        • Site JP00009
      • Ibaraki, Japão
        • Site JP00001
      • Kanagawa, Japão
        • Site JP00008
      • Kanagawa, Japão
        • Site JP00005
      • Okayama, Japão
        • Site JP00003
      • Osaka, Japão
        • Site JP00004
      • Osaka, Japão
        • Site JP00010
      • Osaka, Japão
        • Site JP00011
      • Tokyo, Japão
        • Site JP00007

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos a 74 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

At the time of obtaining informed consent:

  • Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
  • Subject is able to be admitted to the site as scheduled.
  • Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.

At screening period:

  • Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
  • Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
  • Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
  • Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
  • Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.

Exclusion Criteria:

At the time of obtaining informed consent:

  • Subject has type 2 diabetes mellitus.
  • Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
  • Subject has received ASP1941 (ipragliflozin) with the exception of placebo.

At screening period:

  • Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
  • Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
  • Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
  • Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
  • Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
  • Subject with perioperative, severe infection or serious injury.
  • Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
  • Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
  • Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
  • Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
  • Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
  • Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
  • Subject has urinary tract infection or genital infection with subjective symptoms.
  • Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
  • Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
  • Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
  • Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
  • Subject has psychiatric disorder that makes the subject unsuitable for study participation.
  • Subject has drug addiction or alcohol abuse.
  • Subject has a history of drug allergies.
  • Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
  • Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
  • Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo
uma vez por dia
Oral
Experimental: ASP1941 Low dose group
once daily
Oral
Outros nomes:
  • Suglat
  • Ipragliflozina
Experimental: ASP1941 Middle dose group
once daily
Oral
Outros nomes:
  • Suglat
  • Ipragliflozina
Experimental: ASP1941 High dose group
once daily
Oral
Outros nomes:
  • Suglat
  • Ipragliflozina

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Daily profile of plasma glucose levels
Prazo: up to Day 14
up to Day 14
Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels
Prazo: at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-3h of plasma glucose levels
Prazo: at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-4h of plasma glucose levels
Prazo: up to Day 14
up to Day 14
AUC0-10h of plasma glucose levels
Prazo: up to Day 14
up to Day 14
Fasting plasma glucose levels
Prazo: up to Day 21
up to Day 21
Glycoalbumin
Prazo: up to Day 21
up to Day 21
Urinary glucose excretion
Prazo: up to Day 14
up to Day 14
Urinary glucose excretion rate
Prazo: up to Day 14
up to Day 14
Urine volume
Prazo: up to Day 14
up to Day 14
Urinary glucose concentration
Prazo: up to Day 15
up to Day 15
Body weight
Prazo: up to Day 21
up to Day 21
Renal glucose clearance
Prazo: up to Day 14
up to Day 14
Plasma concentration of unchanged ASP1941
Prazo: up to Day 14
up to Day 14
Urinary concentration of unchanged ASP1941
Prazo: up to Day 14
up to Day 14
Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)
Prazo: at Day 1
at Day 1
PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)
Prazo: at Day 1 and Day 14
at Day 1 and Day 14
Safety assessed by vital signs
Prazo: up to Day 21
Supine blood pressure and supine pulse rate
up to Day 21
Safety assessed by 12-lead electrocardiogram
Prazo: up to Day 21
up to Day 21
Safety assessed by laboratory tests
Prazo: up to Day 21
Hematology, biochemistry and urinalysis
up to Day 21
Safety assessed by self-monitored blood glucose levels
Prazo: up to Day 21
up to Day 21
Safety assessed by Adverse events
Prazo: up to Day 21
up to Day 21

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de setembro de 2015

Conclusão Primária (Real)

19 de março de 2016

Conclusão do estudo (Real)

19 de março de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

18 de agosto de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de agosto de 2015

Primeira postagem (Estimativa)

20 de agosto de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de março de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de março de 2019

Última verificação

1 de março de 2019

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 1941-CL-6001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

Não

Descrição do plano IPD

Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .